Join us virtually at BIO Digital 2021 in June and talk to our experts.
BIO Digital is the world's largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators. BioTech naturally has a special focus in times of Covid, where the rapid development of the new vaccines, among many other topics, has shown us how quickly progress can be made in this area. The pandemic has led to shifts in business focus or even changes in business models for many companies.
Recent studies show that contract manufacturers for the pharmaceutical industry, CDMOs (contract development and manufacturing organizations), have so far been little involved in the production of vaccines. This is changing with the outbreak of the Covid-19 pandemic.
Leading CMDOs like Aenova Group can support these challenges as a "full service provider" - from small scale manufacturing of materials for clinical trials, technical transfer to scale up of high volume production of fill and finish of biologics like Covid-19-vaccines.
Fill & Finish of Vaccines
Aenova has just launched a major investment program that includes the installation of further state-of-the-art equipment for aseptic production. With a completely new "fill and finish" area for vials and prefilled syringes with high-speed filling lines including compounding at the Aenova site in Latina, Italy, more than 80 million vials and over 180 million prefilled syringes can be produced there per year. Aenova is also planning a further capacity expansion with up to three additional high-speed filling lines.